Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BELINDA: tisagenlecleucel versus standard of care in relapsed or refractory aggressive B-cell non-Hodgkin lymphoma
2023-508343-48-00Phase 3Completed
- Sponsor
- Novartis
- Start
- May 2024
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 18
01
Overview
Phase 3, randomised, open-label trial in mature B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL) and 2 more comparing Tisagenlecleucel with Standard of care (2 arms). Primary endpoint: Event-free survival. Started May 2024; status: completed.
02
Drugs
tisagenlecleucel
03
Conditions
mature B-cell lymphomadiffuse large B-cell lymphoma (DLBCL)primary mediastinal large B-cell lymphoma (PMBCL)large-cell lymphomafollicular lymphoma (FL)
Beyond the preview
Go deeper on 2023-508343-48-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508343-48-00.